Pricing

Outlook Therapeutics Inc (OTLK)

followers ·
Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
C. Russell Trenary
Employees:
20
485 ROUTE 1 SOUTH, BUILDING F, SUITE 320, ISELIN, NJ, 08830
6096193990
Stock Split History
DateRatio
2019-03-18 1:8
2024-03-14 1:20
Outlook Therapeutics, Inc. focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available